Anakinra in rheumatoid arthritis
Interleukin-1 (IL-1) plays a central role in the pathophysiology of rheumatoid arthritis (RA) . The IL-1 gene family includes IL-1α, IL-lβ and IL-1 receptor antagonist (IL-IRa) , Extracellular IL-lα, which is membrane-associated, and IL- lβ, which is the soluble form, are agonist molecules that can influence the functions of most cell types. Activated monocytes and macrophages are the principal source of IL-la and IL-lβ. There are two distinct IL-1 receptors, designated type I (IL-1RI) and type II (IL-1RII) [3, 4]. IL-1 binding to IL-1RI results in signal transduction and cell activation. IL-1RII is a “decoy” receptor that functions by scavenging IL-la and IL-lβ, but does not have a role in cell signaling . Soluble IL-1RII (sIL-lRII) is important in regulating IL-l-mediated functions. Binding of IL-1 to IL-1RI produces many effects that are central to the pathogenesis of RA [3, 4, 6, 7, 8]. The pivotal role of IL-1 in the pathophysiology of RA was highlighted by inducing the pathologic features of RA in rabbits following transfer of the human IL-lβ gene, resulting in the constitutive expression of IL-lβ by synovial cells .
KeywordsRheumatoid Arthritis Health Assessment Questionnaire Score Infectious Episode Rheumatoid Arthritis Clinical Trial Anakinra Treatment
Unable to display preview. Download preview PDF.
- 9.Ghivizzani SC, Kang R, Georgescu HI, Lechman ER, Jaffurs D, Engle JM, Watkins SC, Tindal MH, Suchanek MK, McKenzie LR et al (1997) Constitutive intra-articular expression of human IL-lβ following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis. J Immunol 159: 3604–3612PubMedGoogle Scholar
- 14.Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist (IL-1ra), in combination with methotrexate. Arthritis Rheum 46: 614–624CrossRefPubMedGoogle Scholar
- 15.Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R et al (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36: 729–740CrossRefPubMedGoogle Scholar
- 16.Nuki G, Bresnihan B, Bear MB, McCabe D (2002) Long-term safety and maintainence of clinical improvement following treatment with anakinra (recombinant human IL-1 receptor antagonist) in patients with rheumatoid arthritis. Extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46: 2838–2846CrossRefPubMedGoogle Scholar
- 18.Bresnihan B, Chan WW, Woolley JM (2001) Increases in productivity after six and twelve months of anakinra treatment in patients with rheumatoid arthritis. Arthritis Rheum 44: S77Google Scholar
- 21.Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, McCabe D (2000) A multicenter, double-blind, dose-ranging, randomized and placebo controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid Anakinra in rheumatoid arthritis arthritis: radiologic progression and correlation of Genant and larsen scoring methods. Arthritis Rheum 43: 1001–1009CrossRefPubMedGoogle Scholar
- 25.Fleishmann R, Tesser J, Schechtman J, Sun G (2002) Safety of anakinra (interleukin-1 receptor antagonist) in rheumatoid arthritis subjects with potential high risk for infection. Arthritis Rheum 46: S343Google Scholar
- 26.Fiirst DE, Breedfeld FC, Kalden JR, Smolen JS, Antoni CE, Bijlsma JWJ, Burmester GR, Cronstein B, Keystone EC, Kavanaugh A, Klareskog L (2002) Updated consensus statement on biologic agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis 61 (Suppl II): ii2–ii7Google Scholar
- 28.Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Biirge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340: 253–259CrossRefPubMedGoogle Scholar
- 30.Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN et al (1998). Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552–1563CrossRefPubMedGoogle Scholar